Munich - Delayed Quote EUR

Ardelyx Inc (41X.MU)

3.6740

-1.1230

(-23.41%)

At close: May 2 at 5:25:25 PM GMT+2

Analysts Have Been Trimming Their Ardelyx, Inc. (NASDAQ:ARDX) Price Target After Its Latest Report

The analysts might have been a bit too bullish on Ardelyx, Inc. ( NASDAQ:ARDX ), given that the company fell short of...

Simply Wall St. 22 hours ago

ARDX
Q1 2025 Ardelyx Inc Earnings Call

Q1 2025 Ardelyx Inc Earnings Call

Thomson Reuters StreetEvents 2 days ago

ARDX
Ardelyx Inc (ARDX) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amid Market Challenges

Ardelyx Inc (ARDX) reports a 61% revenue increase, driven by strong IBSRELA sales, despite facing market disruptions and increased expenses.

GuruFocus.com 2 days ago

ARDX
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 2 days ago

ARDX
Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of -70% and 8.14%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 days ago

ARDX
Ardelyx: Q1 Earnings Snapshot

WALTHAM, Mass. AP) — Ardelyx Inc. ARDX) on Thursday reported a loss of $41.1 million in its first quarter.

Associated Press Finance 2 days ago

ARDX
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million Company ends Q1 with $214.0 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative,

GlobeNewswire 2 days ago

ARDX
High Growth Tech Stocks In The US For May 2025

As the U.S. market experiences a notable upswing, with the S&P 500 and Nasdaq Composite marking gains amid strong earnings reports from major tech companies like Microsoft and Meta, investors are keenly observing how these developments impact high-growth tech stocks. In this environment of robust AI spending and positive sentiment, identifying companies with solid financials and innovative strategies becomes crucial for those looking to tap into the potential of high-growth sectors.

Simply Wall St. 2 days ago

RNG

APLS

ARDX
Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Merdad Parsey, M.D., Ph.D. to the company’s board of directors. “We are thrilled to welcome Merdad to our board of directors,” said Mike Raab, president and chief executive officer of Ardelyx. “Merdad is a veteran

GlobeNewswire 4 days ago

ARDX
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will present data supporting the company’s first-in-class retainagogue, IBSRELA® (tenapanor), as well as results from the IBS in America 2024 supplemental survey, at the upcoming Digestive Disease Week Conference (DD

GlobeNewswire 9 days ago

ARDX
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 1, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2025. To part

GlobeNewswire 16 days ago

ARDX
Is Ardelyx Inc. (NASDAQ:ARDX) the Best Biotech Penny Stock to Buy According to Hedge Funds?

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Ardelyx Inc. (NASDAQ:ARDX) stands against other biotech penny stocks. Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of the […]

Insider Monkey 17 days ago

ARDX
April 2025's Top Penny Stocks To Watch

The market is up 8.4% in the last 7 days, with all sectors gaining ground, and over the past 12 months, it has risen by 5.9%, with earnings forecasted to grow by 13% annually. Penny stocks may be a throwback term, but the opportunities they represent are far from old news; these typically smaller or newer companies present an underappreciated chance for growth at lower price points. When combined with strong balance sheets and solid fundamentals, penny stocks can offer upside without many of...

Simply Wall St. 17 days ago

ARDX

AUTL

PL
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

WALTHAM, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will present a post-hoc analysis of the OPTIMIZE Study, an open-label clinical trial of XPHOZAH ® (tenapanor), as a poster at the National Kidney Foundation (NKF) Spring Clinical Meetings, now underway in Boston. Ard

GlobeNewswire 23 days ago

ARDX
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that an abstract detailing a post-hoc analysis of the OPTIMIZE Study, an open-label clinical trial of XPHOZAH ® (tenapanor), was accepted as a poster presentation at the National Kidney Foundation (NKF) Spring Clinical Meetings, to b

GlobeNewswire last month

ARDX
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

Award established to recognize leaders in the field of chronic kidney disease advocacyWALTHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, is proud to announce on World Kidney Day that Mary Baliker, Erich Ditschman, Nichole Jefferson, Curtis Warfield and David M. White are the first recipients of the

GlobeNewswire last month

ARDX
High Growth Tech Stocks In The US With Promising Potential

Over the last 7 days, the United States market has experienced a 1.7% drop, yet it remains up by 12% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability in an evolving market landscape.

Simply Wall St. last month

ARDX

DAWN

BSY
Ardelyx Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Ardelyx ( NASDAQ:ARDX ) Full Year 2024 Results Key Financial Results Revenue: US$333.6m (up 168% from FY 2023). Net...

Simply Wall St. 2 months ago

ARDX
Ardelyx Says China Approves New Drug Application for Hyperphosphatemia Treatment Tenapanor; Shares Up Pre-Bell

Ardelyx (ARDX) said Wednesday that a new drug application for tenapanor for the treatment of hyperph

PREMIUM
MT Newswires 2 months ago

ARDX

SFOSF
Tenapanor Approved in China for Hyperphosphatemia

Ardelyx to receive $5 million milestone payment from Fosun Pharma following approvalWALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the approval of a New Drug Application (NDA) by China’s Center for Drug Evaluation of the National Medical Products Administration for tenapanor to co

GlobeNewswire 2 months ago

ARDX

Performance Overview

Return	41X.MU	S&P 500 (^GSPC)
YTD	-24.99%	-3.31%
1-Year	-40.24%	+12.29%
3-Year	+108.02%	+36.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ardelyx Inc (41X.MU)

Analysts Have Been Trimming Their Ardelyx, Inc. (NASDAQ:ARDX) Price Target After Its Latest Report

Q1 2025 Ardelyx Inc Earnings Call

Ardelyx Inc (ARDX) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amid Market Challenges

Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics

Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates

Ardelyx: Q1 Earnings Snapshot

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

High Growth Tech Stocks In The US For May 2025

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

Is Ardelyx Inc. (NASDAQ:ARDX) the Best Biotech Penny Stock to Buy According to Hedge Funds?

April 2025's Top Penny Stocks To Watch

Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

High Growth Tech Stocks In The US With Promising Potential

Ardelyx Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Ardelyx Says China Approves New Drug Application for Hyperphosphatemia Treatment Tenapanor; Shares Up Pre-Bell

Tenapanor Approved in China for Hyperphosphatemia

Performance Overview